CKD Clinical Decisions: The Role of SGLT2 Inhibitors
Saturday, April 17, 2021
11:30am - 12:30pm
The management of patients with suspected chronic kidney disease (CKD) involves numerous clinical decisions beginning with considerations for screening and extending through optimal treatment. This activity explores many of these clinical questions encountered by primary care clinicians, with discussion about 2020 guidelines issued by Kidney Disease – Improving Global Outcomes (KDIGO) and the American Diabetes Association (ADA).
After the presentation, participants should be able to:
- Identify the risks and consequences of chronic kidney disease
- Screen appropriately for the presence of CKD in patients at high risk
- Describe the safety and efficacy of SGLT2 inhibitors on renal outcomes inpatients with and without type 2 diabetes mellitus.
- Initiate evidence-based therapy for lowering blood glucose in patients with established kidney disease as recommended in updated guidelines.
Stephen A. Brunton, MD, FAAFP
Adjunct Associate Professor
Touro University California
College of Osteopathic Medicine
Stephen Brunton, MD, FAAFP, has disclosed that he is on the advisory board for Abbott Diabetes, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi and Xeris Pharmaceuticals; as well as on the speakers bureau for Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, and Sanofi.
Kim Zuber, PA-C, disclosed no relevant financial relationship or interest with a proprietary entity producing, marketing, reselling or distributing health care goods or services.
Gregory Scott, PharmD, RPh, Editorial Support, and Michael Hanak, MD, Reviewer, disclosed no relevant financial relationship or interest with a proprietary entity producing, marketing, reselling or distributing health care goods or services.
|All relevant financial relationships have been mitigated.
This CME activity includes discussion about uses of medications outside of their approved labeling.
Thank you for attending 2021 FamMed Forum!
Thank you for participating in the 2021 FamMed Forum. In order to complete this course and qualify for CME Credit, you must be logged into the website.
If the banner above shows "log in to enroll," please do so using the BLUE login button displayed on this page. All registered attendees are enrolled in each FamMed Forum CME Course. (KSA requires separate registration).
Begin by completing the Session Evaluation. Make sure you click "Submit" at the end of the evaluation before continuing to the post-test.
Then complete the brief post-test. If you experience difficulty, please view the How to Claim CME menu item.
At the end of the live meeting, we will provide a link where you can complete your overall session evaluation and claim CME credit for the entire conference, if you wish to do so.
If you have any difficulty or questions, please contact us by email by clicking here.